Premium
Effectiveness of leukotriene receptor antagonism in the postoperative management of chronic rhinosinusitis
Author(s) -
Yelverton Joshua C.,
Holmes Thomas W.,
Johnson Christopher M.,
Gelves Camilo Reyes,
Kountakis Stilianos E.
Publication year - 2016
Publication title -
international forum of allergy and rhinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.503
H-Index - 46
eISSN - 2042-6984
pISSN - 2042-6976
DOI - 10.1002/alr.21649
Subject(s) - medicine , montelukast , sinusitis , asthma , nasal polyps , gastroenterology , endoscopy , chronic rhinosinusitis , adjuvant therapy , surgery , chemotherapy
Background Montelukast is used in the treatment of allergic rhinitis and asthma. It has been used as adjuvant therapy in patients with chronic rhinosinusitis (CRS), but its effectiveness has not been evaluated. This study evaluates the efficacy of adjuvant leukotriene receptor antagonism in CRS and subtypes. Methods Retrospective review of collected data at a tertiary‐referral institution. We identified all patients who were prescribed montelukast postoperatively and had a lapse in therapy for at least 1 month (n = 50), so that the patients themselves serve as their own control group. Twenty‐item Sino‐Nasal Outcomes Test (SNOT‐20) scores and Lund‐Kennedy endoscopy scores were obtained for each patient. Scores were compared with and without montelukast using Wilcoxon signed rank test. The analysis was controlled for changes in other medications. Results Fifty‐two therapy lapses were identified in 50 patients. Twenty‐seven patients had eosinophilic CRS with polyps (eCRSwNP), 8 had Samter's triad (ST), and 15 had allergic fungal sinusitis (AFS). Overall mean follow‐up was 46.5 months. Overall, SNOT‐20 scores and endoscopy scores were significantly lower with montelukast ( p < 0.005 for both). On subgroup analysis, SNOT‐20 scores were significantly improved for patients with eCRSwNP and AFS ( p < 0.001 and p = 0.001, respectively). Endoscopy scores were significantly improved for patients with eCRSwNP ( p = 0.044). Outcomes approached, but did not reach, significance for patients with ST ( p = 0.123 for SNOT‐20 and p = 0.146 for endoscopy). There was also significant improvements in patients with asthma. Conclusion The addition of montelukast as postoperative therapy may be beneficial for patients with eCRSwNP and AFS.